Cure My Disease

Don't miss your cure!

 Log in / Sign up

A glow of hope: UV imaging may reveal how well hair loss treatment will work

NCT ID NCT07803874

Knowledge-focused Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study asks whether a red glow seen under ultraviolet light on the scalp can predict how well hair regrows in people with a type of hair loss called limited plaque alopecia areata. Adults who are already scheduled to receive corticosteroid injections as part of their regular care will have close-up images taken of the affected area. Researchers will track hair regrowth at weeks 4, 8, and 12 to see if the initial red fluorescence intensity relates to how soon and how much hair returns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intralesional triamcinolone acetonide, a corticosteroid injected into the scalp as part of routine care
What this could lead to
If red fluorescence predicts treatment response, doctors might use it to personalize care and set expectations for hair regrowth in alopecia areata.
What could go wrong
This is a small observational study, so the link may not hold in larger groups. Also, the treatment is routine, so the study only tests prediction, not a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with limited plaque-type alopecia areata of the scalp who are receiving intralesional corticosteroid treatment as part of routine clinical care at the dermatology outpatient clinic will be prospectively enrolled. Participants will undergo standardized conventional trichoscopic and UV-trichoscopic assessments and will be followed for 12 weeks to evaluate red fluorescence intensity, trichoscopic findings, and hair regrowth.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Limited plaque-type alopecia areata of the scalp * Active hair loss * Symptom onset within the previous 6 months * No topical, intramuscular, or oral treatment for alopecia areata within the previous 1 month * No intralesional corticosteroid treatment within the previous 6 weeks * Provision of informed consent Exclusion Criteria: * Beard alopecia areata * Very extensive alopecia areata or multiple large plaques * Tinea capitis or active infection * Current phototherapy * Systemic immunosuppressive treatment within the washout period specified in the study protocol * Pregnancy or breastfeeding * Contraindication to UV imaging

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul Training and Research Hospital

    RECRUITING

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.